

## **Ziextenzo** [1]

### **PrZiextenzo** ®

Ziextenzo® (pegfilgrastim injection) is a biologic drug (biosimilar) to Neulasta®.

Ziextenzo® is indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive antineoplastic drugs.

Ziextenzo® is the third Sandoz biosimilar available in Canada.

Click [here](#) [2] [2] to consult the product monograph of Ziextenzo®

\* Ziextenzo® is a registered trademark owned or used under license by Sandoz Canada Inc.

\*\* Neulasta® is a registered trademark of Amgen in Canada.

#### **Publish Date:**

May 06, 2020

#### **Accordion Type:**

Collapsible

---

**Source URL:** <https://www.sandoz.ca/en/products/patients/biosimilars/ziextenzo>

#### **Links**

[1] <https://www.sandoz.ca/en/products/patients/biosimilars/ziextenzo>

[2] <https://www.sandoz.ca/sites/www.sandoz.ca/files/Ziextenzo-Product-Monograph.pdf>